Knockdown (KD) or inhibition of LSD1 reduces the proliferative capacity of cancer cells in different tumor models16,17 and numerous LSD1 inhibitors currently undergo clinical assessment for cancer therapy, particularly for small cell lung cancer (SCLC) and acute myeloid leukemia (AML)18. This evidence concerns the gene KDM1A and acute myeloid leukemia.